Rituximab therapy for life-threatining immune hemolytic anemia in a liver tranplant recipient: a case report
Makaleler > Tam Makale · 2004
Yazarlar: M Akyildiz, Abdullah Zeki KARASU, S Cagirgan, M Kilic, Y Tokat
Transplantation Proceedings, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2004, cilt 36, ss 1492-1493
DOI: 10.1016/j.transproceed.2004.05.042
Özet
Rituximab an anti-CD20 chimeric monoclonal antibody directed against the CD20 antigen on B lymphocytes, has been demonstrated to be highly effective for B-cell depletion. Because of its biological properties, it has become as a treatment option for a variety of autoimmune diseases. We report successful treatment of a 25-year-old male cadaveric liver retransplant recipient who displayed severe immune hemolytic anemia with rituximab, despite no previous response to corticosteroids plus intravenous immune globulin therapy.